Orchard Therapeutics plc, an integrated biopharmaceutical company, focuses on developing various transformative treatments. It dedicated to transform the lives of patients with serious and life-threatening rare diseases through autologous ex vivo gene therapies. The company's gene therapy approach seeks to transform a patient's hematopoietic stem cells into a gene-modified drug product to treat the patient's disease through a single administration. Its commercial stage products include Strimvelis, a gammaretroviral-based product for the treatment of adenosine deaminase-severe combined immunodeficiency (ADA-SCID). The company's clinical development products comprise OTL-101 for the treatment of ADA-SCID; OTL-200 to treat metachromatic leukodystrophy; OTL-103 for the treatment of Wiskott-Aldrich syndrome; OTL-102 for X-linked chronic granulomatous disease; and OTL-300 for transfusion-dependent beta-thalassemia. Its preclinical programs include OTL-201 for mucopolysaccharidosis type IIIA and OTL-202 for mucopolysaccharidosis type IIIB. The company, formerly known as Orchard Rx Limited, was founded in 2015 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ORTX
Previous Symbol
CUSIPN/A
Phone011-44-0-203-3846700
Debt
Debt-to-Equity RatioN/A
Current Ratio1.37
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / Cash FlowN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A
Miscellaneous
Employees100
Outstanding Shares84,050,000
Market Cap$1.28 billion
OptionableNot Optionable
Orchard Therapeutics (NASDAQ:ORTX) Frequently Asked Questions
What is Orchard Therapeutics' stock symbol?
Orchard Therapeutics trades on the NASDAQ under the ticker symbol "ORTX."
What price target have analysts set for ORTX?
4 Wall Street analysts have issued 1 year price targets for Orchard Therapeutics' stock. Their forecasts range from $16.80 to $27.00. On average, they expect Orchard Therapeutics' stock price to reach $21.70 in the next twelve months. This suggests a possible upside of 49.0% from the stock's current price. View Analyst Price Targets for Orchard Therapeutics.
What is the consensus analysts' recommendation for Orchard Therapeutics?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Orchard Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Orchard Therapeutics.
Has Orchard Therapeutics been receiving favorable news coverage?
News stories about ORTX stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Orchard Therapeutics earned a daily sentiment score of 1.2 on InfoTrie's scale. They also gave news stories about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Orchard Therapeutics' key competitors?
Some companies that are related to Orchard Therapeutics include Ablynx (ABLYF), argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Crispr Therapeutics (CRSP), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Rubius Therapeutics (RUBY), Spark Therapeutics (ONCE) and Editas Medicine (EDIT).
Who are Orchard Therapeutics' key executives?
Orchard Therapeutics' management team includes the folowing people:
- Mr. Mark A. Rothera, CEO, Pres, and Director (Age 55)
- Dr. Anne Dupraz-Poiseau, Chief Regulatory Officer
- Mr. Frank E. Thomas, Chief Financial Officer & Chief Bus. Officer (Age 48)
- Prof. Bobby Gaspar, Chief Scientific Officer, Director and Member of Scientific Advisory Board
- Mr. John Ilett, Gen. Counsel & Company Sec.
When did Orchard Therapeutics IPO?
(ORTX) raised $200 million in an initial public offering (IPO) on Wednesday, October 31st 2018. The company issued 13,300,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and Cowen acted as the underwriters for the IPO and Wedbush PacGrow was co-manager.
When did Orchard Therapeutics' quiet period expire?
Orchard Therapeutics' quiet period expired on Monday, December 10th. Orchard Therapeutics had issued 14,285,715 shares in its public offering on October 31st. The total size of the offering was $200,000,010 based on an initial share price of $14.00. During Orchard Therapeutics' quiet period, insiders and any underwriters that worked on the IPO were prevented from issuing any research reports or earnings estimates for the company because of SEC regulations. Now that the company's quiet period has ended, brokerages that served as underwriters are now able to initiate research on the company.
How do I buy shares of Orchard Therapeutics?
Shares of ORTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Orchard Therapeutics' stock price today?
One share of ORTX stock can currently be purchased for approximately $14.56.
How big of a company is Orchard Therapeutics?
Orchard Therapeutics has a market capitalization of $1.28 billion. Orchard Therapeutics employs 100 workers across the globe.
What is Orchard Therapeutics' official website?
How can I contact Orchard Therapeutics?
Orchard Therapeutics' mailing address is 108 CANNON STREET, LONDON X0, EC4N 6EU. The company can be reached via phone at 011-44-0-203-3846700.
MarketBeat Community Rating for Orchard Therapeutics (NASDAQ ORTX)
MarketBeat's community ratings are surveys of what our community members think about Orchard Therapeutics and other stocks. Vote "Outperform" if you believe ORTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ORTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
